Henry Gosebruch, Neumora CEO
November 3, 2023 07:16 AM EDT
Deals

With IPO mon­ey, Neumo­ra eyes deals as CEO brings M&A chops from roles at Ab­b­Vie, JP Mor­gan

Kyle LaHucik

Senior Reporter

Neumo­ra Ther­a­peu­tics, a brain dis­ease biotech born out of stitch­ing to­geth­er mul­ti­ple neu­ro­science star­tups, is look­ing to repli­cate its orig­i­nal play­book by com­ple­ment­ing its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times